Theravance Biopharma (NASDAQ:TBPH) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a research report released on Wednesday morning.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.33.

Theravance Biopharma Stock Down 5.6%

Shares of TBPH stock opened at $8.41 on Wednesday. The firm has a market capitalization of $420.51 million, a price-to-earnings ratio of -8.33 and a beta of -0.10. The stock has a fifty day moving average of $9.17 and a 200 day moving average of $9.29. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Equities research analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares of the company’s stock, valued at $3,330,342. The trade was a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC purchased a new stake in Theravance Biopharma during the 4th quarter valued at about $25,000. GAMMA Investing LLC lifted its stake in shares of Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 3,281 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma in the fourth quarter worth approximately $69,000. Teacher Retirement System of Texas purchased a new stake in shares of Theravance Biopharma during the fourth quarter valued at approximately $103,000. Finally, ClearAlpha Technologies LP bought a new stake in shares of Theravance Biopharma during the fourth quarter valued at approximately $109,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.